Last reviewed · How we verify
Fludarabine, Busulfan, and ATG — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Fludarabine, Busulfan, and ATG (Fludarabine, Busulfan, and ATG) — University of Chicago.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fludarabine, Busulfan, and ATG TARGET | Fludarabine, Busulfan, and ATG | University of Chicago | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fludarabine, Busulfan, and ATG CI watch — RSS
- Fludarabine, Busulfan, and ATG CI watch — Atom
- Fludarabine, Busulfan, and ATG CI watch — JSON
- Fludarabine, Busulfan, and ATG alone — RSS
Cite this brief
Drug Landscape (2026). Fludarabine, Busulfan, and ATG — Competitive Intelligence Brief. https://druglandscape.com/ci/fludarabine-busulfan-and-atg. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab